{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=28", "query": { "intervention": "antibody-drug conjugate", "page": 28 }, "page_size": 10 }, "pagination": { "page": 28, "page_size": 10, "total_count": 503, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=29&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=antibody-drug+conjugate&page=27&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T16:26:12.476Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04843709", "title": "A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "MRG004A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lepu Biopharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2021-07-26", "completion_date": "2024-07-26", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 6, "location_summary": "Orange, California • New York, New York • Canton, Ohio + 3 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Canton", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Gettysburg", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04843709" }, { "nct_id": "NCT02073487", "title": "Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "T-DM1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Abraxane", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 32, "start_date": "2014-02", "completion_date": "2019-01", "has_results": true, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 3, "location_summary": "Houston, Texas • Sugar Land, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073487" }, { "nct_id": "NCT04681131", "title": "CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Cancer" ], "interventions": [ { "name": "CAB-AXL-ADC", "type": "BIOLOGICAL" }, { "name": "PD-1 inhibitor", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioAtla, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2021-03-17", "completion_date": "2025-07-09", "has_results": false, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 32, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 26 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04681131" }, { "nct_id": "NCT00051584", "title": "Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "SGN-15 (cBR96-Doxorubicin Immunoconjugate)", "type": "DRUG" }, { "name": "Gemzar (Gemcitabine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 60, "start_date": null, "completion_date": "2003-05", "has_results": false, "last_update_posted_date": "2011-10-24", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 6, "location_summary": "Tucson, Arizona • San Diego, California • Torrance, California + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Boise", "state": "Idaho" }, { "city": "Arlington", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00051584" }, { "nct_id": "NCT06362252", "title": "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extensive Stage-small Cell Lung Cancer" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2024-07-22", "completion_date": "2028-02-20", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06362252" }, { "nct_id": "NCT05464030", "title": "Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "M9140", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2022-08-04", "completion_date": "2026-10-23", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 6, "location_summary": "Encinitas, California • Fresno, California • Providence, Rhode Island + 3 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Providence", "state": "Rhode Island" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05464030" }, { "nct_id": "NCT07087860", "title": "Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis and Ureter Urothelial Carcinoma", "Refractory Bladder Urothelial Carcinoma", "Refractory Renal Pelvis and Ureter Urothelial Carcinoma", "Stage IV Bladder Cancer AJCC v7", "Stage IV Renal Pelvis and Ureter Cancer AJCC v7" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Central Venous Cannula Insertion", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Plasmapheresis", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Antibody-Drug Conjugate Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2025-08-01", "completion_date": "2028-08-07", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07087860" }, { "nct_id": "NCT06805825", "title": "A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Stromal Tumors", "Small-cell Lung Cancer", "Adenoid Cystic Carcinoma", "Uveal Melanoma", "Neuroendocrine Tumors", "Chromophobe Renal Cell Carcinoma", "Clear Cell Renal Cell Carcinoma" ], "interventions": [ { "name": "NN3201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novelty Nobility, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2025-02-03", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-09-23", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 5, "location_summary": "Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Houston", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805825" }, { "nct_id": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High-risk Muscle Invasive Urothelial Carcinoma" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 915, "start_date": "2026-07-16", "completion_date": "2032-11-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 19, "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07720284" }, { "nct_id": "NCT01026233", "title": "Cardiac Safety Study of Brentuximab Vedotin (SGN-35)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Disease, Hodgkin", "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2010-01", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2014-12-12", "last_synced_at": "2026-11-09T16:26:12.476Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Duarte, California • Stanford, California + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026233" } ] }